Replies to post #204104 on NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

I’m not very knowledgeable about detailed trial process so I don’t know about things like SAP timing opportunities and possible prerequisites. However one significant difference between 2017 and 2018 is the exposition of the tail, which very recently appeared to be deemed established enough for the nwbo’s advisory group to support concluding the trial. So perhaps 2017 was deemed to early and risky towards achieving FDA approval?

Whether LP was using another carrot to lead everyone on to keep the company and trial going, maybe.

At this point with the recent moves with Bigger and Sawston, and Cognate, and the statements of moving to conclusion, it feels like end game. I’ve been wrong before and could be wrong again with this investment, however when I try to analyze the logic and what info is publicly available, I keep coming up long.